The global digital health market is experiencing exponential growth, fueled by advancements in remote monitoring, telehealth, and personalized medicine. Regulatory bodies are increasingly favoring non-invasive diagnostic tools that enhance patient safety and comfort. This technology aligns perfectly with these trends, offering a competitive edge to companies seeking to innovate in chronic disease management, preventive care, and clinical trials, where accurate, non-intrusive data collection is paramount for market leadership.
Eliminates invasive blood sampling by using non-invasive liquid and membrane measurement, reducing patient physical and mental stress by approximately 80%.
Simplifies system setup and operation, shortening examination preparation time by approximately 30% and significantly improving healthcare workflow.
Enables pressure estimation based on membrane shape measurement, with potential application across a wide range of biometric sites, from deep internal organs to superficial tissues.
This patent, granted after overcoming six prior art references and thorough examination, represents a robust and stable right. Its claims have been meticulously drafted with strong legal representation, ensuring a low invalidation risk. This technology provides a clear differentiator for biometric pressure measurement, establishing a strong legal foundation for long-term business development.
The patent protects the core non-invasive pressure measurement system. Licensees could develop additional IP in AI-driven diagnostic algorithms or integrate it with other physiological sensors for comprehensive health monitoring platforms.
If a licensee provides diagnostic devices incorporating this technology to hospitals, it could reduce consumable and labor costs for traditional invasive examinations by approximately 30% for 10,000 tests annually (assuming $33.50/case (AI est.)). This yields a direct cost reduction of ~$100K/year (AI est.). Additionally, indirect medical cost savings from reduced patient hospitalization and complication risks could lead to a total market impact of ~$1.0M/year (AI est.).
X: Deployment & Operational Cost Efficiency
Y: Measurement Accuracy & Practicality